Biogen | BIIB - Srodki Pieniężne I Ekwiwalent

Cena Akcji
192.83
Dzienna Zmiana
9.45 5.15%
Miesięcznie
2.80%
Rocznie
59.26%
Q2 Prognozy TE
180.43




Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Amgen USD 9.13B 316M 2025-12
Bayer EUR 5.9B 1.34B 2025-09
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Gilead Sciences USD 7.56B 234M 2025-12
Incyte USD 4.02B 435.22M 2026-03
Merck USD 18.17B 10.16B 2025-09
Moderna USD 2.6B 1.46B 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novartis USD 11.44B 1.88B 2025-12
Pfizer USD 1.34B 295M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
United Therapeutics USD 1.56B 217M 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12